News items Newborn screening in sight through the discovery of novel disease biomarkers by new technique
8 July 2021

The door has finally opened on screening newborn babies for pyridoxine-dependent epilepsy (PDE), a severe inherited metabolic disorder. This screening promises to enable better and earlier treatment of the disease. To identify new biomarkers that can be used in the newborn screening protocol, also known as the neonatal heel prick, researchers at the Radboud University Medical Center joined forces with scientists at the Radboud University’s HFML-FELIX laboratory. They published their findings in The Journal of Clinical Investigation.

The discovery and identification of the new biomarkers could lead to an important addition to worldwide newborn screening protocols. Currently, there are over a thousand known inborn metabolic diseases (IMD), but only 2% of them can be detected through the neonatal heel prick. While these are relatively rare as individual disorders, in the Netherlands, every other day a child is born with an IMD. These disorders have severe health consequences for patients and are currently one of the leading causes of early death among children in the Netherlands.

Technologies combined

“Using new techniques in our clinical laboratory where we study the products of chemical processes (metabolomics), we were able to detect the presence of compounds in body fluids of patients that are not present in persons unaffected by PDE – that was a great first step. However, we could only identify the exact structure of these compounds, the new PDE biomarkers, using the infrared laser at FELIX”, says Karlien Coene, laboratory specialist and researcher at the Translational Metabolic Laboratory of the Radboud University Medical Center. This is the first time that an infrared free electron laser – of which are only a hand full in the world – is combined with these clinical experiments.

Pyridoxine-dependent epilepsy (PDE) is an inherited metabolic disorder that is primarily characterized by intractable seizures that do not respond to conventional antiepileptic medications. Seizures are often controlled by daily high doses of vitamin B6, however 80% of affected children nevertheless suffer developmental delay and intellectual disability.

Early screening for metabolic diseases is critical for optimal treatment. That is why researchers are constantly looking for new ways to detect more metabolic diseases earlier in life via the heel prick. These diseases can be identified by looking for the presence of small molecules in the blood that are unique to the disease, also called “biomarkers”.

Circumvent bottlenecks

Biomarker discovery and identification is a well-known bottleneck in research of metabolic diseases. “To overcome this hurdle, we decided to combine the advanced analytical instrumentation with the infrared laser of the FELIX laboratory’, says Jonathan Martens, researcher at Radboud University’s FELIX Laboratory. “The measurements obtained using the unique FELIX laser gives us information about the bonds between the atoms and leads us to the precise molecular structure. With this information, we ultimately managed to synthesize the molecules and this allowed us to further investigate their role in the disease.”

In addition to new possibilities in newborn screening, this finding has also revealed fundamental insights about the disease, which could ultimately lead to optimized treatment and better chances to prevent cognitive disability.

Martens: “Now that we have demonstrated that this new combination of techniques really works, we are actively applying our method in research on a range of other (metabolic) diseases for which biomarkers are currently lacking.”

Read more

Related news items


ScreenPoint Medical raises $28 million for further development Series C funding led by Insight Partners

2 August 2021

ScreenPoint Medical has raised $28 million in a Series C financing. ScreenPoint Medical is a spin-off of the Radboudumc.

read more

Senior Kolff Fellowship for Jeroen de Baaij

29 July 2021

Jeroen de Baaij, theme Renal disorders, received a prestigious Senior Kolff grant from The Dutch Kidney Foundation. His project aims to establish dietary approaches against vascular calcification in chronic kidney disease.

read more

Differences in the number of de novo mutations between individuals due to small family-specific effects and stochasticity

28 July 2021

Christian Gilissen and colleagues investigated whether there is a family-specific contribution to the number of de novo mutations in the DNA of offspring and published the results in the Genome Research.

read more

Christa Sperna Weiland, Erwin van Geenen and Joost Drenth discuss the best strategy to prevent post-endoscopic retrograde cholangiopancreatography pancreatitis

28 July 2021

Christa Sperna Weiland, Erwin van Geenen and Joost Drenth, published in Lancet Gastroenterology & Hepatology a systematic review and network meta-analysis to determine the most efficacious prophylaxis strategy to prevent post-endoscopic retrograde cholangiopancreatography pancreatitis.

read more

ZonMw Gender in Research competition awarded to Genderful Research World Consortium

27 July 2021

Natalia Valdrighi and Esmeralda Blaney Davidson won the competition to create a plan for the dissemination of the knowledge and skills gained during the Gender in Research workshop amongst their peers, colleagues and institution, financed by ZonMw and CIHR-IGH in Canada.

read more

Young people with colorectal cancer deserve their own treatment

27 July 2021

Richarda de Voer and Marjolijn Ligtenberg's study on clinical, pathological, genetic and molecular characteristics of colorectal tumors in adolescents and adults 25 years of age or younger is published in Clinical Gastroenterology and Hepatology.

read more